Business Information
The company's principal activities are to discover, develop and commercialize novel antibody-based products for the prevention and treatment of serious bacterial and fungal infections in the hospital setting. The company has two product candidates in late-stage clinical development. The veronate product is developed to prevent hospital-associated infections in premature, very low birth weight, infants. Aurexis, another product is developed to treat serious, life-threatening staphylococcus aureus, bloodstream infections in hospitalized patients. In addition, the company has three preclinical product candidates that are being developed to prevent and treat serious infections. The operations are carried on in the United States.
|
|
Name |
Title
|
Email
|
| Michael Henos | Chmn. | N/A | | Russell Plumb | Dir., CEO, Pres. | N/A | | Joseph Patti | Co - Founder, Chief Scientific Officer, Sr. VP - Research, Development | N/A | | Amy Morris | VP - Clinical Development | N/A | | Geoffrey Henson | Sr. VP - Drug Development | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 846 | (31,145) | | 2005 | 936 | (38,575) | | 2004 | 650 | (25,911)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
